The once-daily tablet also trimmed weight about 4% over 13 weeks, with no dropouts from stomach side effects, the company reports. Obesity phase III data are due in 2028.
Recap by typeshit. Full story at PR Newswire.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
The pair plan to supply licensed compounders if the FDA adds the peptides to its bulk substance list. GLP-1 drugs are left out of the deal.
CNA Lifestyle asked doctors how the oral and injectable forms of Wegovy differ and what risks people should weigh before trying either.
Loading…